UMIN000049936
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational Study
Graduate School of Medicine, Osaka University·University Hospital Medical Information NetworkRecruiting
Study focus
- Disease/Condition
- Non-small cell lung cancer
- Study type
- Observational
Sponsor & location
- Primary sponsor
- Graduate School of Medicine, Osaka University
- Location
- Japan
Timeline & enrollment
- Phase
- N/A
- Start date
- Mar 02, 2023
- End date
- N/A
ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- University Hospital Medical Information Network
- Trial ID
- UMIN000049936
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for UMIN000049936 through Pure Global AI's free database. This phase not specified trial is sponsored by Graduate School of Medicine, Osaka University and is currently Recruiting. The study focuses on Non-small cell lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to University Hospital Medical Information Network data, helping medical device and pharmaceutical companies navigate clinical research efficiently.